{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-03b6a8-2023-04-12T17:09:41+01:00",
"date": "2023-04-12T17:09:41+01:00",
"ocid": "ocds-h6vhtk-03b6a8",
"initiationType": "tender",
"tender": {
"id": "C153405",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs",
"status": "active",
"classification": {
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
},
"mainProcurementCategory": "services",
"description": "NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf ofNHS England (referred to as the Commissioner), is inviting suitably qualified andexperienced providers to respond to this invitation to tender (ITT) exercise to commissionhaemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs.The haemophilia ATMP treatment hub allocation model is as follows:Lot 1 - One site to cover the NHS England population in the East of EnglandLot 2 - Two sites to cover the NHS England population in LondonLot 3 - One site to cover the NHS England population in the MidlandsLot 4 - One site to cover the NHS England population in the North East of England andYorkshireLot 5 - One site to cover the NHS England population in the North West of EnglandLot 6 - One site to cover the NHS England population in the South East of EnglandLot 7 - One site to cover the NHS England population in the South West of EnglandPlease note that providers must be located in the defined geographical catchment area(s) that they are interested in providing services to.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"lotDetails": {
"maximumLotsBidPerSupplier": 1,
"maximumLotsAwardedPerSupplier": 1
},
"lots": [
{
"id": "1",
"title": "Lot 1 - One site to cover the NHS England population in the East of England",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
},
{
"id": "2",
"title": "Lot 2 - Two sites to cover the NHS England population in London",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
},
{
"id": "3",
"title": "Lot 3 - One site to cover the NHS England population in the Midlands",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
},
{
"id": "4",
"title": "Lot 4 - One site to cover the NHS England population in the North East of Englan",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
},
{
"id": "5",
"title": "Lot 5 - One site to cover the NHS England population in the North West of Englan",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
},
{
"id": "6",
"title": "Lot 6 - One site to cover the NHS England population in the South East of Englan",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
},
{
"id": "7",
"title": "Lot 7 - One site to cover the NHS England population in the South West of Englan",
"description": "The key objectives of the Procurement are to commission Haemophilia ATMP treatment
hubs for patients with haemophilia types A and B to serve the population of England, and to
ensure that:
* the providers of Haemophilia ATMP treatment hubs have the correct qualifications and
governance arrangements in place to provide these treatments for the NHS in England, and
* the Commissioner is offering services that are safe and of a high standard whilst fulfilling
the Commissioner's public duty to provide services that are cost-effective.
The National Institute for Health and Care Excellence (NICE) will be assessing a number of
ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected
NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for
patients with haemophilia types A and B. NHS England is seeking to commission eight of the
18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP
treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by
NICE with a contract duration of 8 years with the option to extend for up to a further 18
months.
For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately,
NHS England will work with the UKHCDO to develop a thorough care pathway detailing the
responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to
manage the care of haemophilia patients undergoing ATMP treatment.
Given the significant amount of preparatory work that needs to be undertaken to deliver a
gene therapy service, it is not feasible for commissioners and providers to wait until NICE has
made its recommendations to commence commissioning activity.
Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that
the product does not receive a positive NICE recommendation.
Providers wishing to be considered for the delivery of these services will need to respond to
the provider selection documentation and submit responses prior to the deadline stated in
this notice.
The ITT documentation including a questionnaire is available through the Atamis (Health
Family) portal: https://health-family.force.com/s/Welcome. The reference is C153405 and
the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.
There will also be an opportunity to attend a market engagement event via Microsoft Teams
at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please
email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and
questions and responses will be made available to all bidders following the event.",
"value": {
"amount": 1000000,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2023-12-16T00:00:00Z",
"endDate": "2031-12-15T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "As a result of this procurement exercise an agreement will be established with the successful
Bidders for a period of 8 years with the Commissioner having the option to extend the
Contract for up to a further 18 months. It is anticipated that the contract start date will be
16th December 2023 which is 90 days following the expected final NICE guidance; however,
this may be subject to change."
},
"status": "active"
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKH"
}
],
"relatedLot": "1"
},
{
"id": "2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKI"
}
],
"relatedLot": "2"
},
{
"id": "3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKF"
}
],
"relatedLot": "3"
},
{
"id": "4",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKC"
}
],
"relatedLot": "4"
},
{
"id": "5",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKD"
}
],
"relatedLot": "5"
},
{
"id": "6",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKJ"
}
],
"relatedLot": "6"
},
{
"id": "7",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
}
],
"deliveryAddresses": [
{
"region": "UKK"
}
],
"relatedLot": "7"
}
],
"submissionMethod": [
"electronicSubmission",
"written"
],
"submissionMethodDetails": "https://health-family.force.com/s/Welcome",
"communication": {
"atypicalToolUrl": "https://health-family.force.com/s/Welcome"
},
"selectionCriteria": {
"criteria": [
{
"type": "suitability",
"description": "As detailed within the ITT documents",
"appliesTo": [
"supplier"
]
}
]
},
"documents": [
{
"id": "economic",
"documentType": "economicSelectionCriteria"
},
{
"id": "technical",
"documentType": "technicalSelectionCriteria"
}
],
"contractTerms": {
"performanceTerms": "As detailed within the ITT documents"
},
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"coveredBy": [
"GPA"
],
"tenderPeriod": {
"endDate": "2023-05-05T12:00:00+01:00"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"durationInDays": 120
}
},
"awardPeriod": {
"startDate": "2023-05-05T12:00:00+01:00"
},
"bidOpening": {
"date": "2023-05-05T12:00:00+01:00"
},
"hasRecurrence": false,
"amendments": [
{
"id": "1",
"unstructuredChanges": [
{
"oldValue": {
"date": "2023-05-05T12:00:00+01:00"
},
"newValue": {
"date": "2023-05-10T10:00:00+01:00"
},
"where": {
"section": "II.2.7.4",
"label": "End date"
}
}
]
}
]
},
"parties": [
{
"id": "GB-FTS-67205",
"name": "NHS England",
"identifier": {
"legalName": "NHS England",
"noIdentifierRationale": "notOnAnyRegister"
},
"address": {
"streetAddress": "1st Floor, Quarry House, Quarry Hill",
"locality": "Leeds",
"region": "UKE",
"postalCode": "LS2 7UE",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Josselin Canevet",
"email": "josselin.canevet@nhs.net",
"url": "https://health-family.force.com/s/Welcome"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.england.nhs.uk//",
"buyerProfile": "https://www.england.nhs.uk//",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-68884",
"name": "NHS Arden and GEM CSU",
"identifier": {
"legalName": "NHS Arden and GEM CSU"
},
"address": {
"streetAddress": "Francis Crick House",
"locality": "Northampton",
"postalCode": "NN3 6BJ",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody",
"mediationBody",
"reviewContactPoint"
],
"details": {
"url": "https://www.ardengemcsu.nhs.uk/"
}
}
],
"buyer": {
"id": "GB-FTS-67205",
"name": "NHS England"
},
"language": "en"
}